We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q3
Read MoreHide Full Article
ABIOMED, Inc. reported third-quarter fiscal 2021 earnings per share (EPS) of $1.17, which beat the Zacks Consensus Estimate by 1.7%. Also, the figure improved 5.4% year over year.
Revenues in Detail
Revenues of $231.7 million beat the Zacks Consensus Estimate by 2.9%. The metric also rose 4.6% from the prior-year quarter.
Q3 in Detail
U.S. Impella product revenues totaled $179.6 million, reflecting a rise of 1% year over year. However, per management, U.S. patient usage of the Impella heart pumps fell 2% in the quarter, mainly due to the coronavirus pandemic.
Outside the United States, Impella product revenues totaled $41.2 million, highlighting an increase of 17% year over year. Japan Impella product revenues and service improved 38% while European Impella product revenues grew 11% year over year.
Margin Trend
In the quarter under review, gross profit totaled $190.6 million, up 4.9% year over year. Gross margin in the quarter was 82.3% of net revenues, highlighting an expansion of 31 basis points (bps) year over year.
Total operating costs came in at $119.2 million, up 7.1% from the prior-year quarter.
Operating profit totaled $71.4 million, up 1.6% on a year-over-year basis. Operating margin was 30.8%, down 91 bps.
The company exited the third quarter of fiscal 2021 with $181 million of cash and cash equivalents compared with $202.2 million at the end of the fiscal second quarter.
Cash flow from operating activities came in at $79.1 million in the fiscal third quarter.
The balance sheet was also debt free as of Dec 31, 2020.
Guidance
For the fiscal fourth quarter, global revenues are projected in the range of $225-$235 million, indicating 9-14% growth from the figure reported in fourth-quarter fiscal 2020.The Zacks Consensus Estimate for the same is pegged at $229.6 million.
Summing Up
ABIOMED exited the third quarter of fiscal 2021 on a strong note. Impella revenues in Europe and Japan improved in the quarter under review. Product launches and regulatory approvals continue to buoy optimism. Also, the company saw a rise in U.S. Impella revenues.
The recent FDA 510(k) clearance for the company’s Breethe OXY-1 cardiopulmonary bypass support system is a positive. Notably, the company witnessed a deleveraged balance sheet in the quarter under review. During the fiscal third quarter, the Impella ECP heart pump completed the first phase of its FDA early feasibility study (EFS). The company also attained an FDA 510(k) clearance for its Expandable and Recoilable (XR) Sheath with regard to the Impella 2.5.
However, the company’s flagship Impella saw lower patient usage within the United States. Contraction in the operating margin is also worrying.
Zacks Rank
ABIOMED currently carries a Zacks Rank #3 (Hold).
Key Picks
Some better-ranked stocks, which are expected to report earnings soon, include Hologic, Inc. (HOLX - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Align Technology, Inc. (ALGN - Free Report) .
The Zacks Consensus Estimate for Hologic's first-quarter fiscal 2021 adjusted EPS is pegged at $2.14, indicating a whopping increase of 250.8% from the year-ago quarter’s reported number. The company currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
IDEXX currently carries a Zacks Rank #2 (Buy). The Zacks Consensus Estimate for fourth-quarter 2020 adjusted EPS currently stands at $1.43, indicating growth of 37.5% from the prior-year quarter’s reported figure. The consensus estimate for fourth-quarter revenues is pegged at $677.5 million, reflecting a 12.2% increase from the year-ago period’s reported figure.
The Zacks Consensus Estimate for Align Technology’s fourth-quarter 2020 revenues is pegged at $781.9 million, implying a 20.3% increase from the year-earlier period’s reported figure. The same for EPS stands at $2.13, indicating growth of 39.2% from the year-ago quarter’s reported number. The company currently carries a Zacks Rank of 2.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q3
ABIOMED, Inc. reported third-quarter fiscal 2021 earnings per share (EPS) of $1.17, which beat the Zacks Consensus Estimate by 1.7%. Also, the figure improved 5.4% year over year.
Revenues in Detail
Revenues of $231.7 million beat the Zacks Consensus Estimate by 2.9%. The metric also rose 4.6% from the prior-year quarter.
Q3 in Detail
U.S. Impella product revenues totaled $179.6 million, reflecting a rise of 1% year over year. However, per management, U.S. patient usage of the Impella heart pumps fell 2% in the quarter, mainly due to the coronavirus pandemic.
Outside the United States, Impella product revenues totaled $41.2 million, highlighting an increase of 17% year over year. Japan Impella product revenues and service improved 38% while European Impella product revenues grew 11% year over year.
Margin Trend
In the quarter under review, gross profit totaled $190.6 million, up 4.9% year over year. Gross margin in the quarter was 82.3% of net revenues, highlighting an expansion of 31 basis points (bps) year over year.
Total operating costs came in at $119.2 million, up 7.1% from the prior-year quarter.
Operating profit totaled $71.4 million, up 1.6% on a year-over-year basis. Operating margin was 30.8%, down 91 bps.
ABIOMED, Inc. Price, Consensus and EPS Surprise
ABIOMED, Inc. price-consensus-eps-surprise-chart | ABIOMED, Inc. Quote
Financial Condition
The company exited the third quarter of fiscal 2021 with $181 million of cash and cash equivalents compared with $202.2 million at the end of the fiscal second quarter.
Cash flow from operating activities came in at $79.1 million in the fiscal third quarter.
The balance sheet was also debt free as of Dec 31, 2020.
Guidance
For the fiscal fourth quarter, global revenues are projected in the range of $225-$235 million, indicating 9-14% growth from the figure reported in fourth-quarter fiscal 2020.The Zacks Consensus Estimate for the same is pegged at $229.6 million.
Summing Up
ABIOMED exited the third quarter of fiscal 2021 on a strong note. Impella revenues in Europe and Japan improved in the quarter under review. Product launches and regulatory approvals continue to buoy optimism. Also, the company saw a rise in U.S. Impella revenues.
The recent FDA 510(k) clearance for the company’s Breethe OXY-1 cardiopulmonary bypass support system is a positive. Notably, the company witnessed a deleveraged balance sheet in the quarter under review. During the fiscal third quarter, the Impella ECP heart pump completed the first phase of its FDA early feasibility study (EFS). The company also attained an FDA 510(k) clearance for its Expandable and Recoilable (XR) Sheath with regard to the Impella 2.5.
However, the company’s flagship Impella saw lower patient usage within the United States. Contraction in the operating margin is also worrying.
Zacks Rank
ABIOMED currently carries a Zacks Rank #3 (Hold).
Key Picks
Some better-ranked stocks, which are expected to report earnings soon, include Hologic, Inc. (HOLX - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Align Technology, Inc. (ALGN - Free Report) .
The Zacks Consensus Estimate for Hologic's first-quarter fiscal 2021 adjusted EPS is pegged at $2.14, indicating a whopping increase of 250.8% from the year-ago quarter’s reported number. The company currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
IDEXX currently carries a Zacks Rank #2 (Buy). The Zacks Consensus Estimate for fourth-quarter 2020 adjusted EPS currently stands at $1.43, indicating growth of 37.5% from the prior-year quarter’s reported figure. The consensus estimate for fourth-quarter revenues is pegged at $677.5 million, reflecting a 12.2% increase from the year-ago period’s reported figure.
The Zacks Consensus Estimate for Align Technology’s fourth-quarter 2020 revenues is pegged at $781.9 million, implying a 20.3% increase from the year-earlier period’s reported figure. The same for EPS stands at $2.13, indicating growth of 39.2% from the year-ago quarter’s reported number. The company currently carries a Zacks Rank of 2.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot stocks we're targeting >>